Compare Cassava Sciences Inc (FLNA) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Wells Fargo & Co — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Wells Fargo & Co trades at $88.28 (market cap $265.03B). The key difference: Wells Fargo & Co is far larger — about 4987.4× Cassava Sciences Inc's market cap, and Wells Fargo & Co pays a 2.06% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | WFC | |
|---|---|---|
Market Cap | $53.14M | $265.03B |
Sector | Health | Financials |
52-Week High | $4.64 | $96.40 |
52-Week Low | $1.09 | $73.42 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Wells Fargo (WFC) trades at $88.125, up 3.04% today, with a bullish technical signal and strong Q2 2026 earnings beat. The stock shows improving fundamentals with net income margin at 25.97% and a P/E of 12.72, supported by recent dividend payments and growth initiatives. News highlights robust earnings season performance and AI investments in wealth management.
Outlook remains positive with analyst consensus price target of $97.36, though risks include net interest margin pressure and volatile cash flows. Upside potential exists from loan growth and efficiency gains, but investors should monitor expense trends and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
